Zai Lab posts Q3 2026 loss, raises $250 million and outlines 2027 product milestones

Zai Lab reported third‑quarter 2026 product revenue of $108.2 million, a net loss of $46.1 million and cash of $659.7 million. The company closed a private placement that netted about $250 million to fund pipeline work. It highlighted phase‑I data for its zoci ADC showing an 81.8% confirmed response rate, an estimated 81.9% six‑month progression‑free survival and 9.1% grade ≥ 3 adverse events, and said three registrational studies are slated for 2027.

The $250 million financing gives Zai Lab runway to advance its lead oncology and immunology programs, including a global Phase III trial for zoci. The loss and modest revenue growth signal short‑term cash burn, but the cash balance of $659.7 million should cover operating needs through the next year.

  • 1Total product revenue was $108.2 million in Q3 2026, a 2% sequential increase.
  • 2Net loss for the quarter was $46.1 million, or $0.04 per ADS.
  • 3Cash, cash equivalents and short‑term investments totaled $659.7 million as of September 30 2026.
  • 4The private placement closed on October 27 2026, delivering net proceeds of approximately $250.0 million.
  • 5Zoci 1.6 mg/kg plus atezolizumab achieved an 81.8% confirmed objective response rate in the Phase I study.
  • 6The same regimen showed an estimated 81.9% six‑month progression‑free survival rate.

Sources